Information  X 
Enter a valid email address

Synairgen plc (SNG)

  Print      Mail a friend       Annual reports

Friday 02 October, 2020

Synairgen plc

Appointment of Joint Broker

RNS Number : 8826A
Synairgen plc
02 October 2020

Synairgen plc


('Synairgen' or the 'Company')


Appointment of Joint Broker


Southampton, UK - 2 October 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, is pleased to announce the appointment of Numis Securities Limited as Joint Broker to the Company with immediate effect. finnCap remains Nominated Adviser and Joint Broker to the Company.



For further enquiries, please contact:


Synairgen plc

Richard Marsden, Chief Executive Officer

John Ward, Finance Director

Tel: + 44 (0) 23 8051 2800


finnCap (Nominated Advisor & Joint Broker)

Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)

Alice Lane, Manasa Patil (ECM)

Tel: + 44 (0) 20 7220 0500


Numis Securities Limited (Joint Broker)

James Black, Freddie Barnfield

Tel: +44 (0) 20 7260 1000


Consilium Strategic Communications (Financial Media & Investor Relations)

Mary-Jane Elliott, Sue Stuart, Olivia Manser

[email protected]

Tel: +44 (0) 20 3709 5700


Notes for Editors


About Synairgen

Synairgen is a respiratory drug discovery and development company founded by University of

Southampton Professors Stephen Holgate, Donna Davies, and Ratko Djukanovic. The

business, focused primarily on lung viral defence in asthma, COPD, and COVID-19, uses its

differentiating human biology BioBank platform and world-renowned international academic

KOL network to discover and develop novel therapies for respiratory disease. Synairgen is

quoted on AIM (LSE: SNG). For more information about Synairgen, please see

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t